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Spinal Cord Stimulation in Diabetic Lower Limb Critical Ischaemia:
Transcutaneous Oxygen Measurement as Predictor for Treatment
Success
I. E. Petrakis∗ and V. Sciacca
1st Department of General Surgery ‘‘Policlinico Umberto’’, University of Rome, ‘‘La Sapienza’’, Rome, Italy
Objectives: to evaluate whether transcutaneous oxygen tension (TcpO2) measurements could be used as a specific
prognostic parameter in selecting diabetic patients for permanent device implantation.
Methods: sixty consecutive diabetic patients (28 with autonomic neuropathy), classified as Fontaine stage III or IV,
underwent spinal cord stimulation (SCS) for ischaemic pain, after failed conservative or surgical treatment. Pedal TcpO2
on the dorsum of the foot and ankle-pressure Doppler measurements were performed before, and 2 and 4 weeks after
implantation.
Results: limb salvage and good pain relief were achieved in 35 patients, while in 12 partial pain relief and limb salvage
for at least 6 months were obtained. In 13 patients the method failed and the ischaemic limbs were amputated. Only 3 of
the 28 patients with neuropathy had any long-term benefit. Limb salvage was achieved in those patients with a significant
increase in TcpO2 within 2 weeks of stimulation. The stage of the neuropathy was inversely related to the success of SCS
therapy. The ankle–brachial pressure index (ABPI) did not change after stimulation.
Conclusions: diabetic patients with significant increase of TcpO2 and pain relief during a 2-week test period may be
successfully treated by long-term SCS unless they have advanced autonomic neuropathy.
Key Words: Spinal cord stimulation; Diabetes; Neuropathy; Lower-limb ischaemia; Transcutaneous oxygen tension
(TcpO2).
Introduction been applied in the effort to quantify the SCS effect on
blood flow. Transcutaneous oxygen tension (TcpO2)
Spinal cord stimulation (SCS) seems an established measured by Clark’s electrode seems to be a reliable non-
invasive method of tissue perfusion, useful for assessingtreatment for patients with peripheral arterial occlusive
disease (PAOD).1–5 Initially, the method was used to PAOD.11–18 TcpO2 measurement has already been used as
a predictive parameter to evaluate ulcer-healing in end-manage patients with chronic intractable pain,7 or to
improve motor function in patients with partial spinal stage vascular patients treated with SCS.11
The efficacy of SCS in diabetic patients with severecord lesions.7 SCS has also been used successfully to
manage diabetic patients with advanced peripheral lower-limb ischaemia and peripheral neuropathy has
not, to our knowledge, been investigated before. Theneuropathic pain.8 Peripheral neuropathy is a common
long-term complication of diabetes8 and about 7.5% of purpose of this prospective study was to investigate
whether the TcpO2 measurements before and duringthediabeticpopulationhave painfulneuropathicsymp-
toms, mainly affecting the lower limb.9 the SCS treatment in diabetic patients could be used
to predict therapy success and to select patients forSCS has beneficial effects on peripheral blood flow of
the lower limbs, with improvement of walking ability, permanent device implantation.
healing of trophic lesions, increase in cutaneous tem-
perature and reduction or disappearance of skin dis-
coloration.10 Non-invasive (Doppler, rheology, Patients and Methods
plethysmography, thermography) and invasive (201Ti
muscle scintigraphy, xenon133 clearance) techniques have Sixty consecutive insulin-dependent type I diabetic
patients, 35 men, 25 women (28 with autonomic neur-
opathy), mean age 60 years (range 46–75) with non-re-∗ Please address all correspondence to: I. E. Petrakis, Via Roma 95
Vasanello (VT), I-01030 Italy. constructible PAOD of the lower limbs and ischaemic
1078–5884/00/060587+06 $35.00/0  2000 Harcourt Publishers Ltd.
I. E. Petrakis and V. Sciacca588
pain were selected, by an independent vascular surgeon, chair. The flow plan, in order, for performing tests of
cardiovascular autonomic function was the following:from the outpatients attending our institution. The me-
dian duration of their diabetes was 22 (range 15–40)
(A) Tests reflecting cardiac parasympathetic damage:years.Patientsunderwentafullhistoryandexamination,
(1) Heart-rate response to Valsalva manoeuvrewhich included the assessment of neuropathic symp-
(patient position: sitting);toms and deficit scores. Local exclusion criteria included
(2) Heart-rate (R-R intervaal) variation during deepunmeasurable ankle pressure due to non-compressible
breathing (sitting);calcifiedarteries,deepulceration,osteomyelitis,wetgan-
(3) Immediate heart-rate response to standing (lyinggrenous lesions >3 cm2, peripheral neuropathy due to
5–10 min to standing).other causes (e.g. alcohol) and inability to perform se-
(B) Tests reflecting cardiac sympathetic damage;lective angiography. Systemic exclusions included a life-
(4) Blood-pressure response to standing (lyingexpectancy of less than 18 months due to concomitant
5–10 min to standing) anddiseases, significant heart failure, severe pulmonary or
(5) Blood-pressure response to sustained handgriprenal insufficiency, unstable angina, a non-cooperative
(sitting).patient and spinal disease.
The duration of vascular history ranged from 6 Orthostatic hypotension was defined as a drop of
months to more than 6 years. Prior to implantation, at least 20 mmHg in systolic or diastolic blood pressure
all patients had received conservative treatment (pen- upon standing. All the subjects were carefully in-
toxiphylline, antiplatelet agents, defibrotide, bu- structed before test start. The neuropathic score, ran-
flomedil), including management of risk factors, pain ging from 0 to 5, was calculated assigning zero for
therapy (tricylic antidepressants, non-steroid anti-in- normal values, one point for every abnormal test and
flammatories, or dihydrocodeine plus paracetamol) half a point for borderline value test. Early neuropathy
and surgical foot care. was defined as an abnormality of one of the three tests
Intra-arterial subtraction or intraoperative selective of parasympathetic function, and definite neuropathy
arteriograms were obtained from all patients and corresponded to two or more abnormal para-
showed occluded distal vessels, unsuitable for a bypass sympathetic tests with or without abnormal sym-
procedure or angioplasty. If only ankle or foot arteries pathetic tests. The 28 patients with diabetic neuropathy
were available to bypass, but autogenous vein un- had one or more complications of diabetes mellitus
available, the patient was regarded as non-re- such as retinopathy, peripheral neuropathy and neph-
constructible. Failed bypass-procedures in the ropathy. In 15 patients early autonomic neuropathy
involved leg were noted in 27 patients, while, in 24, (1–1.5 points in five patients and 2 in 10 patients) and in
exploration of tibial or/and popliteal arteries dem- 13 patients definite autonomic neuropathy combined
onstrated advanced diabetic atherosclerotic disease. with sympathetic damage (from 2.5 to 3.5) were found.
Five patients had a contralateral amputation. Twenty
diabetic patients Fontaine’s stage III (7 with neur-
opathy) with ischaemic rest pain of at least two months’
duration, 20 diabetic patients stage IV (9 with neur-
Transcutaneous oxygen tension (TcpO2) protocolopathy) with ulcers <3 cm2 and 20 (12 with neuropathy)
with trophic lesions >3 cm2 with dry gangrene of one
TcpO2 (in mmHg) at the dorsum of the foot was meas-or two toes, were included in the present study and
ured using the Microspan Combo TcpO2/pCO2 moni-were treated with SCS. All patients gave informed
toring system (Biochem International Inc., WI, U.S.A.),consent to participate in the study.
to evaluate the reduction in skin circulation. The se-
verity of PAOD was accurately determined using the
TcpO2, which is known to correlate with the clinicalAssessment of autonomic neuropathy
stage of the disease.12–18 The TcpO2 was measured by
Clark’s electrode and seems to be a reliable non-invasiveAutonomic neuropathy was evaluated using the
cardiovascular autonomic neuropathy tests according indexof tissueperfusion,useful forassessingperipheral
arterial occlusive disease.12–16 The electrode, attached toto Ewing and Clarke.19 These tests give a practical
guide that we consider reliable, reproducible, simple the dorsum of the foot, was warmed to 44 °C, causing
maximum vasodilatation of the underlying skin cir-and non-invasive. The total time required was about
20 min and the equipment needed includes a sphygmo- culation and was allowed to stabilise on the skin for 15
minutes before the measurement was taken.13,15 TcpO2manometer, an electrocardiograph, an aneroid man-
ometer, a handgrip dynamometer, plus couch and measurements were performed with the transducer
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placed at the same site, marking the skin with per- feeling of warmth in the painful area indicated optimal
stimulation. The setting parameters were pulse amp-manent ink, at the dorsum of the foot before, 2 and 4
weeks after SCS device implantation, with the patient litude between 1.0 and 5.0 V, frequency between 40
and 120 pps and pulse width from 150 to 450 ms.in a supine position in a controlled room temperature
(25 °C), after a rest lasting at least 30 min. Stimulation was continuous, lasting 24 h a day to
obtain the maximum information on the clinical out-Systolic arterial ankle and toe pressures (in mmHg)
were measured using bi-directional Doppler ultra- come. During follow-up the parameters of stimulation
can be reset with the help of a portable computer,sonography in the posterior tibial and pedal arteries,
respectively and then in the toe artery. The ABPI was according to the patient clinical status.
determined by dividing systolic ankle pressure by
systolic brachial artery pressure.
Statistical analysis
Clinical improvement and pain relief evaluation The TcpO2 data were calculated as mean values and
standard deviations. Paired t-tests with appropriateAnalysis of patient pain relief and clinical improvement correction to reduce type-I errors and Fisher’s exactwere evaluated before implantation, then 2 and 4 weeks test were applied. A p value of <0.05 was consideredafter. Thereafter patients were seen every three months statistically significant.for a minimum of 18 months. The presence of com-
fortable paraesthesia instead of pain, feelings of
warmth, reduction in size of the trophic lesions, im-
Resultsprovement of the pain-free walking interval under
standard conditions (treadmill), an uninterrupted
All patients experienced some pain relief during the testsleep, were evaluated. The pain relief and the method
stimulation period. Among the 20 patients with restsuccess were based on the intake of analgesic drugs
pain, limb salvage for more than 18 months and pain(minor or narcotics) and patients’ self-evaluation using
relief >75% were obtained in 15. Partial success wasa visual analogue scale (VAS). Success was defined as
achieved in four patients (pain relief >50% and limbpain relief of >75% and limb salvage for at least 18
salvage for at least 6 months). In one patient SCS failedmonths with only minor amputation (toe). Partial suc-
to salvage the limb and the patient underwent majorcess was defined as limb salvage for at least 6 months
amputation within 6 months (Table 1). Among the 20associated with pain relief evaluated between 50% and
patients with trophic lesions <3 cm2, limb salvage for70%. Failure was defined as pain relief evaluated as
more than 18 months and pain relief >75% were ob-<50% and limb loss within the first 6 months.
tained in 12 patients. Four patients initially had ameli-
oration of their ischaemic pain >50% but it recurred
after 6–18 months requiring additional analgesic ther-Implantation technique
apy. Severe ischaemic pain recurred in four patients
within the first 6 months after implantation requiringA quadripolar electrode (Pisces-Quad 3487A, Med-
tronic, Minneapolis, MN, U.S.A.) was placed in the major amputation (Table 1). Among the 20 patients with
trophic lesions >3 cm2 (dry gangrene), limb salvage forepidural space by percutaneous lumbar puncture be-
tween L2 and L3 or L3 and L4. The electrode was more than 18 months and pain relief >75% were ob-
tained in eight patients, while in four patients partialpositioned in the midline in most cases, under fluoro-
scopic guidance up to level T10–11. Connecting a success with pain relief >50% and limb salvage for at
least 6 months (mean 9 months range 6–12) wasportable stimulator to the electrode allowed intra-
operative test stimulation producing comfortable par- achieved. After this period the ischaemic pain recurred
and major amputation was unavoidable. The otheraesthesias in the painful foot or limb. The clinical
effects were tested during a 2-week trial period and eight patients initially achieved minor pain relief <50%
but within 2 months additional analgesic medicationin the cases where the patient had a significant pain
relief, an implantable pulse generator (Itrel II IPG, wasnecessary.Within6monthsall thesepatientsunder-
went major amputation (Table 1).Medtronic Inc. Minneapolis, U.S.A.) was placed in an
abdominal subcutaneous pocket. Various settings of TcpO2 foot values, within the first 2 weeks of the
test period, increased from 21.4 s.d. 5.7 mmHg to 31.5the active quadripolar extremities of the electrode were
studied to evaluate the most appropriate combination s.d. 5.4 mmHg (p=0.030) in the patients with rest pain
and limb salvage. In the patients with trophic lesionsfor pain relief. The presence of paraesthesia and a
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Table 1. Pain relief and clinical results after SCS treatment. The These patients were mainly those with rest pain with-
diabetic patients with therapy success (A) achieved a pain relief out neuropathy. The 25 patients with only partial>75% and long-term limb salvage, while those with partial success
(B) achieved a pain control >50% with or without intake of minor success or failure of the method were among the 28
analgesics and limb salvage for at least 6 months. Patients with patients with neuropathy (early or definite) as reported
SCS failure (C) underwent major amputation after a short time- in Table 4. In only three patients (two with rest pain andperiod from the implantation (<6 months).
one with trophic lesions <3 cm2) with early neuropathy
A B C did SCS therapy have a long-term positive effect.
Patients with early neuropathy had a better outcomeRest pain, 20 patients 15 4 1
Trophic lesions <3 cm2, 20 patients 12 4 4 compared to those with definite neuropathy (p=0.008)
Trophic lesions >3 cm2, 20 patients 8 4 8 (Table 4). Eleven of 13 patients where the method
Overall series, 60 patients 35 12 13 failed to save the limb within the first 6 months had
definite (combined) neuropathy (p<0.001). The overall
success and partial success rate for SCS therapy was
<3 cm2, and limb salvage, TcpO2 mean foot values, 78%, while in 22% the method failed.
showed an average improvement from 15.1 s.d. 6.4 to
22.0 s.d. 5.1 mmHg (p=0.030) (Table 2). In patients
with trophic lesions >3 cm2 (dry gangrene) and limb
salvage, after 2 weeks of test period, TcpO2 increased Discussion
from 12.1 s.d. 5.1 to 17.9 s.d. 4.7 mmHg (p=0.025)
(Table 2). Major changes in TcpO2 values were achieved Angiopathy and autonomic neuropathy is a common
long-term diabetic complication.20,21 The pain varieswithin the first 2 weeks after temporary implantation,
while a further, but minimal, increase of TcpO2 after from mild paraesthesia in a few toes to severe un-
remitting pain in both legs.9,22 Night-time exacerbation4 weeks was revealed in the diabetic patients with
limb salvage, compared to the values obtained before of the pain plus contact hypersensitivity to bedclothes
results in loss of sleep.9 The cause of chronic sensory–treatment. Changes of TcpO2 in all diabetic amputees,
where SCS failed to control the ischaemic pain and to motor diabetic neuropathy or indeed neuropathic pain
is not known although metabolic and microvascularsave the limb, were not significant either after 2 or 4
weeks from the device implantation (Table 3). No systems may be involved.23,24 Whilst the search for
potential therapeutic agents to halt or reverse thesignificant changes were observed in the ABPI or toe-
pressure values before permanent implantation (test neuropathic process continues,24 current treatment is
largely aimed at pain relief. Some authors have dem-period) and during the follow-up.
The patients with long-term SCS success had an onstrated that, in patients with PAOD, SCS recruits
small capillaries not ordinarily perfused, enhancingimpressive clinical course, with comfortable par-
aesthesia instead of pain, feelings of warmth, improved skin blood flow, improvements that may explain the
beneficial clinical effects experienced by thesepain-free walking interval under standard conditions
(treadmill), reduction in size of the trophic lesions, patients.12,26 However, their data and the use of SCS
in the treatment of POAD were recently criticised,and undisturbed sleep without requiring analgesics.
Table 2. Mean (S.D.) of TcpO2 (mmHg) value changes in the diabetics with limb salvage for at least 6 months (therapy success or
partial succcess) before treatment, after temporary implantation and 4 weeks after implantation.
Before treatment After 2 weeks p Value After 4 weeks p Value
Rest pain, 19 patients 21.4 (5.7) 31.5 (5.4) =0.030 32.4 (6.4) =0.025
Trophic lesions <3 cm2 16 patients 15.1 (6.4) 22.0 (5.1) =0.030 24.2 (6.2) =0.025
Trophic lesions >3 cm2 12 patients 12.1 (5.1) 17.9 (4.7) =0.025 20.7 (5.3) =0.020
Table 3. Mean (S.D.) of TcpO2 (mmHg) value changes, before treatment, after testing period and 4 weeks after implantation, in the
diabetic patients with failure of the SCS therapy to salvage the limb for at least 6 months.
Before treatment After 2 weeks p Value After 4 weeks p Value
Rest pain, 1 patient 18.1 19.4 NS∗ 20.2 NS
Trophic lesions <3 cm2, 4 patients 14.7 (5.1) 15.4 (4.8) NS 16.1 (3.7) NS
Trophic lesions >3 cm2, 8 patients 9.1 (5.6) 9.6 (4.9) NS 10.8 (5.8) NS
∗Non-significant.
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Table 4. Outcome of the SCS treatment in 28∗ PAOD diabetic patients according to the neuropathic stage of the diabetic disease.
Partial success was achieved in 10 patients with early neuropathy vs. 2 with definite (p=0.008)∗∗ while in 11 patients with definite
neuropathy vs. two with early the method failed (p<0.001)∗∗
Early neuropathy Definite neuropathy
Partial success Failure Partial success Failure
Rest pain (7 patients)∗ 3 1 1 –
Trophic lesions <3 cm2 (9 patients)∗ 4 – — 4
Trophic lesions >3 cm2 (12 patients) 3 1 1 7
Total (25 patients)∗ 10 2 2 11
∗ In two rest-pain diabetic patients and one with trophic lesions <3 cm2 with early autonomic neuropathy, SCS therapy success was
achieved.
∗∗ Fisher’s exact test.
because the indications for SCS implantation have not with severe PAOD is over 80%,13,15 while authors report
a positive predictive value of 77% in the detection ofbeen defined. In critical limb ischaemia, the aim of the
SCS should be not only the effective analgesia (which ischaemia, when a cut-off value of 30 mmHg was
applied as in our series of patients.18 The TcpO2 changesnowadays might be obtained by other less expensive
techniques), but also to obtain limb salvage. related to an increase in skin perfusion, are not a result
of improved arterial inflow.1,35 SCS has no effect onThis study investigated for the first time whether in
patients with PAOD and diabetes, the severity of the macrocirculation,31,32 as demonstrated by the absence
of ABPI modifications after stimulation. The feeling ofautonomic neuropathy should be assessed before a de-
cision for permanent implantation is taken. Applying warmth and paraesthesia caused by SCS was probably
related to the increased TcpO2 due to amelioration ofthe simple tests allow clinicians to give some diagnostic
precision to the autonomic abnormalities presented in the microcirculation.
In diabetic patients with definite neuropathy the20–40% of the diabetic population.27,28 The relief of isch-
aemic pain with SCS is probably secondary to the posi- vasomotor tone is already affected.23,24,27,28 Indeed, in
our study these PAOD patients achieved minimaltive effects on microcirculation rather than vice versa.
Pain relief may also result in attenuation of sympathetic TcpO2 changes before and after SCS treatment, despite
the relief of the neuropathic pain, which was alwaysactivity with vasodilatation, leading to further pain re-
lief. The inhibitory effects of SCS on the transmission of obtained. The diabetic patients with neuropathy gen-
erally had a worse course after SCS treatment that wasnociceptive impulses may be exerted segmentally29 in
the spinal cord and/or at a supraspinal level.29 Clinical inversely related to the stage of neuropathy. During the
test stimulation all implanted patients noted im-observations indicate that the mechanisms involved in
the stimulation-induced relief of ischaemic pain are dif- mediate significant pain relief, while only those with
limb salvage achieved significant increase of TcpO2ferent from those related to relif of other types of pain.30
Indeed, nociceptive pain is more resistant to SCS and value following stimulation. It is our opinion that
PAOD diabetic patients with additional autonomicsignificant pain relief is almost never obtained before a
couple of days, while neuropathic pain of peripheral neuropathy, without significant increase of TcpO2 after
2 weeks of the testing period, should be excluded fromorigin responds well and directly to SCS.31,32 Both com-
ponents, nociceptive as well as neuropathic, are present permanent device implantation for reasons of lack of
long-term success and cost effectiveness.in ischaemic pain. Several authors have postulated that
the principal factor in the relief of ischaemic pain is the All diabetic patients who benefited from SCS had a
significant increase of TcpO2 within the first 2 weeksinhibition of the pain signal per se, leading to a decrease
in sympathetic activity and improved skin micro- of the temporary implantation, suggesting that this
time is appropriate as testing period. The success ofcirculation.31–33 Another hypothesis is that stimula-
tion depresses autonomic sympathetic activity and the therapy and limb salvage depends on the obtained
differences of TcpO2 values before and after im-affects30,34 vasomotor tone by improving cutaneous cir-
culation in ischaemic limb and could be assessed by the plantation rather than the stage of the disease. Indeed,
patients with partial success or failure of the methodTcpO2 measurement.12–18
Assessment of TcpO2 measurement, a non-invasive even with high initial value of TcpO2 but with minimal
change after implantation, whatever the stage of themethod, is reliable and suitable for evaluation of skin
circulation and has been chosen to evaluate micro- disease, had amputation within 6 months after SCS
therapy. The sympathetic activity in these cases iscirculatory changes induced by SCS in many stud-
ies.12–16 The accuracy of the method in selecting patients probably depressed and the vasomotor tone and the
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14 Hauser CL, Shoemaker WC. Use of transcutaneous pO2 regionalabsence of advanced neuropathy the vascular com- perfusion index to quantify tissue perfusion in peripheral vas-
cular disease. Ann Surg 1983; 197: 337–343.pliance and the microcirculation in these patients are
15 Katsamouris A, Brewster DC, Megerman J et al. Trans-affected by the advanced calcified process and are
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likely to have poor results after SCS therapy. J Surg 1984; 147: 510–517.
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